London based Cytospire Therapeutics has announced an $83m series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors
Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.
3 days ago
BioVenture VoiCes Episode 39: SV Health Investors' Kate Bingham
Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more. Chapters Intro and early life - 0:57 School and early work at Vertex - 7:24 Joining SV - 22:30 Early Investment Strategies - 32:40 UK & US - 45:42 Dementia Discovery Fund - 53:18 MedTech - 102:00 Recent d
4 days ago
Biotech's movers for the week of April 27th and a nod to regulatory flexibility for a promising new pancreatic cancer therapy
Reviewing some of biotech's biggest movers of the week including Veradermics, KalVista, Compass Therapeutics, Erasca, Summit Therapeutics, and more.
5 days ago
.png){kind=logo}
